BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
Daniel B. Costa(Beth Israel Deaconess Medical Center), Susumu Kobayashi(Harvard University)
Cited by 490
Related Papers
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
|Journal of Clinical Oncology|2011|590
Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling
|Cancer Research|2006|149
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
|Lung Cancer|2013|93
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
|JTO Clinical and Research Reports|2020|81